On Thursday, Pfizer Inc. (NYSE:PFE) announced that, based on results from the ongoing Phase 1 pharmacokinetic study, it has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose optimization studies in the second half of 2024, evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies. Also Read: What’s Going On With Pfizer On Thursday? Pharma Giant’s Shares Tick Lower. “Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and ...